The total prevalent cases of chronic hepatitis b (CHB) in the seven major markets (7MM*) are projected to increase at an annual growth rate (AGR) of 0.04% from nearly 3.89 million in 2024 to 3.90 million in 2034. In contrast, the diagnosed prevalent cases of CHB are projected to decrease at an AGR of -0.13% from 2.09 million in 2024 to 2.06 million in 2034, according to GlobalData, a leading data and analytics company.

GlobalData’s latest report, “Chronic Hepatitis B: Epidemiology Forecast to 2034” estimates that in 2034, Japan will have the highest number of total prevalent cases of CHB in 7MM, with approximately 1.06 million cases, whereas Spain will have the fewest total prevalent cases with approximately 286,000 cases. This distribution is the same for diagnosed prevalent cases of CHB, with Japan having the highest number of diagnosed CHB prevalent cases at approximately 578,000, while Spain will have the fewest, with around 144,000 cases.

Molly Moran, Senior Epidemiologist at GlobalData, comments: “Despite being preventable by a widely available vaccine, CHB persists as a public health problem across the 7MM due to inadequate screening and treatment coverage.”

Warring factors drive CHB trends. Widespread vaccination and effective efforts to prevent transmission decrease the total prevalent cases of CHB, while broadened access to testing and improved case finding across the 7MM cause diagnosis of this treatable disease to increase.

Moran concludes: “Continued focus on and investment in prevention of initial infection, especially in children, will result in fewer CHB cases requiring lifelong care.”

*7MM: The US, France, Germany, Italy, Spain, the UK, and Japan.